PYC Therapeutics (ASX:PYC) 3-Year RORE % : 10.48% (As of Dec. 2025)


ASX:PYC PYC Therapeutics Ltd ASX:PYC
36 GF Score
Price A$1.54
! 2 Warning Signs
View Full Analysis

What is PYC Therapeutics 3-Year RORE %?

PYC Therapeutics ASX:PYC -4.95% 36 3-Year RORE % is 10.48 as of Dec. 2025. GuruFocus rates ASX:PYC with a GF Score™ of 36/100. The stock has 2 warning signs investors should review. Among 1,293 Biotechnology companies, PYC Therapeutics ranks better than 74.25% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. PYC Therapeutics's 3-Year RORE % for the quarter that ended in Dec. 2025 was 10.48%.

The industry rank for PYC Therapeutics's 3-Year RORE % or its related term are showing as below:

ASX:PYC's 3-Year RORE % is ranked better than
74.25% of 1293 companies
in the Biotechnology industry
Industry Median: -11.55 vs ASX:PYC: 10.48

PYC Therapeutics  (ASX:PYC) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


PYC Therapeutics 3-Year RORE % Related Terms


PYC Therapeutics 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for PYC Therapeutics's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PYC Therapeutics 3-Year RORE % Chart

PYC Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 40.63 13.93 7.88 25.12 11.58

PYC Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.49 25.12 15.19 11.58 10.48

ASX:PYC vs VRTX, REGN, ALNY: 3-Year RORE % Comparison

For the Biotechnology subindustry, PYC Therapeutics's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PYC Therapeutics 3-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PYC Therapeutics's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where PYC Therapeutics's 3-Year RORE % falls into.


ASX:PYC
36GF Score
PYC Therapeutics Ltd ASX:PYC
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PYC Therapeutics 3-Year RORE % Calculation

PYC Therapeutics's 3-Year RORE % for the quarter that ended in Dec. 2025 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.083--0.057 )/( -0.248-0 )
=-0.026/-0.248
=10.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of 10.48 mean?
PYC Therapeutics (ASX:PYC) has a 3-Year RORE % of 10.48 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on PYC Therapeutics and its competitors. According to the industry distribution chart, PYC Therapeutics ranks #333 out of 1293 companies in the Biotechnology industry, placing it in the top 25.8%.
Is PYC Therapeutics' 3-Year RORE % too high?
PYC Therapeutics' current 3-Year RORE % is 10.48. Based on the distribution chart, PYC Therapeutics ranks #333 out of 1293 companies in the Biotechnology industry, which is above the industry midpoint. Overall, PYC Therapeutics has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does PYC Therapeutics' 3-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PYC Therapeutics ranks #333 out of 1293 companies for 3-Year RORE %. This puts PYC Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on PYC Therapeutics and its competitors. PYC Therapeutics's current 3-Year RORE % is 10.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PYC Therapeutics stock overvalued right now?
PYC Therapeutics (ASX:PYC) has a current 3-Year RORE % of 10.48. The current 3-Year RORE % is 10.48. PYC Therapeutics' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For PYC Therapeutics (ASX:PYC), the current 3-Year RORE % is 10.48 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PYC Therapeutics Business Description

Other Exchanges PYCXF:USA
Address 6 Verdun Street, Harry Perkins Institute of Medical Research, Nedlands, Perth, WA, AUS, 6009
PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company's drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.
36GF Score

Get the complete analysis for ASX:PYC

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.54
Price